UCB SA (OTCMKTS:UCBJY - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $107.38 and last traded at $105.02, with a volume of 44013 shares. The stock had previously closed at $105.37.
Analyst Ratings Changes
Separately, The Goldman Sachs Group upgraded shares of UCB to a "strong-buy" rating in a research report on Wednesday, July 16th.
Get Our Latest Stock Report on UCBJY
UCB Stock Performance
The company has a quick ratio of 0.99, a current ratio of 1.36 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average of $94.84 and a 200 day moving average of $93.26.
About UCB
(
Get Free Report)
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UCB, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.
While UCB currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
